Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 18/20 | 0.53 |
| ▸ | SPIN1 | Q9Y657 | 2/20 | 0.49 |
| ▸ | EHMT1 | Q9H9B1 | 2/20 | 0.49 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.49 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.49 |
| ▸ | NSD2 | O96028 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL20336845 | 0.93 | EHMT2 (0.57) | EHMT2SPIN1EHMT1CARM1PRMT1 | |
| Trifluoroacetic Acid SCHEMBL29966595 | 0.93 | EHMT2 (0.57) | EHMT2SPIN1EHMT1CARM1PRMT1 | |
| SCHEMBL23227235 | 0.93 | EHMT2 (0.55) | EHMT2SPIN1EHMT1PRMT1NSD2 | |
| SCHEMBL20351121 | 0.93 | EHMT2 (0.55) | EHMT2SPIN1EHMT1PRMT1NSD2 | |
| Trifluoroacetic Acid SCHEMBL20303963 | 0.92 | EHMT2 (0.56) | EHMT2SPIN1EHMT1CARM1PRMT1 | |
| Trifluoroacetic Acid SCHEMBL29966618 | 0.92 | EHMT2 (0.56) | EHMT2SPIN1EHMT1CARM1PRMT1 | |
| Trifluoroacetic Acid SCHEMBL30509181 | 0.92 | EHMT2 (0.55) | EHMT2SPIN1EHMT1CARM1PRMT1 | |
| Trifluoroacetic Acid SCHEMBL20336854 | 0.92 | EHMT2 (0.55) | EHMT2SPIN1EHMT1CARM1PRMT1 | |
| SCHEMBL20351034 | 0.91 | EHMT2 (0.55) | EHMT2SPIN1EHMT1PRMT1NSD2 | |
| Formic Acid SCHEMBL20336864 | 0.90 | EHMT2 (0.53) | EHMT2SPIN1EHMT1CARM1PRMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4063358-B1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2024-05-22 | — | — | EP | disclosed |
| US-11713299-B2 | Histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| EP-4063358-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | Global Blood Therapeutics, Inc. (US) | 2022-09-28 | — | — | EP | disclosed |
| EP-3558971-B1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2022-02-23 | — | — | EP | disclosed |
| US-20210107876-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2021-04-15 | — | — | US | disclosed |
| US-10829452-B2 | Histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| US-20180186745-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2018-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186745-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, EZH2 | EHMT2 2/4885SPIN1 323/4885EHMT1 1/4885 |
| US-10829452-B2 | Histone methyltransferase inhibitors | EHMT1, DOT1L, EHMT2 | EHMT2 3/4885SPIN1 578/4885EHMT1 1/4885 |
| US-20210107876-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, EZH2 | EHMT2 2/4885SPIN1 323/4885EHMT1 1/4885 |
| US-11713299-B2 | Histone methyltransferase inhibitors | EHMT1, DOT1L, EHMT2 | EHMT2 3/4885SPIN1 533/4885EHMT1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.